Patient-specific medicine access support for Ghana.
MBH Pharma coordinates professional product, source, documentation and delivery enquiries when a treating clinician identifies a patient-specific need. Every case remains subject to the applicable Ghana FDA pathway, supplier confirmation and clinical responsibility.
A case-specific route
A clinician-led need. An operationally coordinated response.
Named-patient access is not a general stock request or a promise of supply. It begins with an exact requirement from a treating clinician or eligible healthcare institution and continues only when the relevant product, supplier, documents and authority route can be aligned.
Ghana FDA’s published named-patient procedure specifically addresses limited imports of unregistered biological products, including vaccines. Other medicine types may require a different regulatory pathway.
Read the Ghana FDA guidance- Request origin
- Treating clinician or eligible healthcare institution
- Case basis
- Patient-specific, product-specific and pathway-specific
- MBH role
- Product, source, document and delivery coordination
- Decision
- Applicable authority and responsible clinical professionals
Working sequence
Four checks before a product moves.
- 01
Clinician-led requirement
The treating clinician or eligible institution identifies the exact medicine, strength, form, pack, intended quantity and patient-specific need. Clinical responsibility remains with the treating clinician.
- 02
Product, source and pathway check
MBH Pharma clarifies registration status, potential manufacturer or authorised supplier, source-market information and which Ghana FDA process may apply.
- 03
Documentation and route readiness
Relevant product information, importer details, English-language labels and inserts, storage conditions and transport requirements are coordinated for review.
- 04
Decision before movement
No purchase or shipment proceeds until the required authority decision, supplier confirmation and operational route are in place. An enquiry may stop at any stage.
Responsibility boundary
Coordination without overstating the pathway.
MBH Pharma can coordinate
- Exact product and source information
- Supplier and non-clinical document questions
- Labelling, storage and transport requirements
- Operational next steps after the applicable decision
MBH Pharma does not
- Prescribe or determine clinical suitability
- Replace the treating clinician or healthcare institution
- Grant Ghana FDA permission or guarantee approval
- Guarantee availability, timing or delivery
Professional enquiries only
Start with the product requirement—not patient-identifiable information.
Send the medicine or INN, strength, form, pack, quantity, institution and target timing. Do not include a patient name, ID, clinical record or other identifiable information in the initial enquiry.
Prepare a named-patient enquiry